A Prospective, Open-Label Trial of Comparing the Pathology Status of Lymphoseek-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection

Trial Profile

A Prospective, Open-Label Trial of Comparing the Pathology Status of Lymphoseek-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Cervical cancer
  • Focus Diagnostic use
  • Sponsors Navidea Biopharmaceuticals
  • Most Recent Events

    • 21 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Oct 2018.
    • 21 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2018.
    • 03 Apr 2017 Planned End Date changed from 1 May 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top